ATE66143T1 - Feste zubereitung mit langsamer freisetzung. - Google Patents

Feste zubereitung mit langsamer freisetzung.

Info

Publication number
ATE66143T1
ATE66143T1 AT85300215T AT85300215T ATE66143T1 AT E66143 T1 ATE66143 T1 AT E66143T1 AT 85300215 T AT85300215 T AT 85300215T AT 85300215 T AT85300215 T AT 85300215T AT E66143 T1 ATE66143 T1 AT E66143T1
Authority
AT
Austria
Prior art keywords
slow release
solid preparation
release solid
sodium
alginate
Prior art date
Application number
AT85300215T
Other languages
English (en)
Inventor
Rodney Dr Horder
Michel Dr Banks
Thomas Herbert Hoadley
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE66143T1 publication Critical patent/ATE66143T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
AT85300215T 1985-01-11 1985-01-11 Feste zubereitung mit langsamer freisetzung. ATE66143T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19850300215 EP0188040B1 (de) 1985-01-11 1985-01-11 Feste Zubereitung mit langsamer Freisetzung

Publications (1)

Publication Number Publication Date
ATE66143T1 true ATE66143T1 (de) 1991-08-15

Family

ID=8194116

Family Applications (1)

Application Number Title Priority Date Filing Date
AT85300215T ATE66143T1 (de) 1985-01-11 1985-01-11 Feste zubereitung mit langsamer freisetzung.

Country Status (7)

Country Link
US (1) US4842866A (de)
EP (1) EP0188040B1 (de)
AT (1) ATE66143T1 (de)
CA (1) CA1273873A (de)
DE (1) DE3583799D1 (de)
ES (1) ES8705757A1 (de)
GR (1) GR860060B (de)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3583799D1 (de) * 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
EP0250572A1 (de) * 1986-01-03 1988-01-07 The University Of Melbourne Zusammensetzung gegen den gastro-desophagenstrom
CA1302659C (en) * 1986-10-24 1992-06-09 Hans-Peter K. Gribi Dental impression material
EP0275336A1 (de) * 1987-01-20 1988-07-27 Knoll Ag Arzneimittelzubereitung mit protahierender Wirkung
US5064736A (en) * 1988-03-23 1991-11-12 Olin Corporation Electrostatic method for multicolor imaging from a single toner bath
DE4002281A1 (de) * 1990-01-26 1991-08-01 Lohmann Therapie Syst Lts Transdermales therapeutisches system mit dem wirkstoff tulobuterol
NL9002008A (nl) 1990-09-12 1992-04-01 Stichting Centr Diergeneeskund Recombinant dna en rna en daarvan afgeleide produkten.
FR2676364B1 (fr) * 1991-05-17 1993-09-10 Lafon Labor Composition pharmaceutique a base de derives d'aminobutanone.
US5368862A (en) * 1991-12-18 1994-11-29 Merck & Co., Inc. Sustained release tablets containing alginate
US5411746A (en) * 1993-02-24 1995-05-02 Warner-Jenkinson Company, Inc. Dye compositions and methods for film coating tablets and the like
US5670169A (en) * 1993-12-20 1997-09-23 E.R. Squibb & Sons, Inc. Wound hydrating gel with novel preservative system and low cytotoxicity
US6692766B1 (en) * 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
DE4443358A1 (de) * 1994-12-06 1996-06-13 Basf Ag Depot-Arzneimittel
US5879712A (en) * 1995-06-07 1999-03-09 Sri International Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
US5811126A (en) * 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US20050064033A1 (en) * 1997-04-11 2005-03-24 Notario Gerard F. Extended release formulations of erythromycin derivatives
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
SI20108B (en) * 1997-06-11 2001-12-31 Abbott Lab A controlled release formulation for poorly soluble basic drugs
IN186245B (de) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US7022683B1 (en) * 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
BG65116B1 (bg) * 2000-01-06 2007-03-30 Abbott Laboratories Лекарствена форма с контролирано освобождаване наслабо разтворими основни лекарствени средства
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
PL366021A1 (en) * 2000-02-29 2005-01-24 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US6642276B2 (en) * 2001-10-01 2003-11-04 M/S Ind-Swift Limited Controlled release macrolide pharmaceutical formulations
EP1443910A1 (de) * 2001-11-02 2004-08-11 Wockhardt Limited Zubereitungen mit kontrollierter freigabe von makrolidantibiotika
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
WO2003105810A1 (en) * 2002-06-14 2003-12-24 Andrx Corporation Pharmaceutical compositions for drugs having ph-dependentsolubility
SI21300A (sl) * 2002-10-08 2004-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Farmacevtske formulacije z alginati
US20100092562A1 (en) * 2002-11-26 2010-04-15 Hollenbeck R Gary Sustained-release drug delivery compositions and methods
GB0230034D0 (en) * 2002-12-23 2003-01-29 Biochemie Gmbh Organic compounds
US7063862B2 (en) * 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
CA2673334C (en) * 2003-06-16 2013-11-12 Andrx Pharmaceuticals, Llc Oral extended-release composition
US20050053658A1 (en) * 2003-09-09 2005-03-10 Venkatesh Gopi M. Extended release systems for macrolide antibiotics
WO2005009365A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005009368A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005009364A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
WO2005023184A2 (en) 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005027877A1 (en) 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US20050084540A1 (en) * 2003-10-17 2005-04-21 Indranil Nandi Taste masking antibiotic composition
US8168228B2 (en) * 2003-10-17 2012-05-01 Sandoz Ag Antibiotic clarithromycin micropellet compositions
US20050101547A1 (en) * 2003-11-06 2005-05-12 Sadatrezaei Mohsen Stabilized azithromycin composition
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
AU2005209843B2 (en) 2004-01-30 2012-02-16 The Johns Hopkins University Nitroxyl progenitor compounds and methods of use
US20050260263A1 (en) * 2004-05-18 2005-11-24 Panion & Bf Biotech Inc. Sustained release formulation for sparingly soluble main drugs
WO2006004795A2 (en) 2004-06-25 2006-01-12 The Johns Hopkins University Angiogenesis inhibitors
WO2006014427A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US20070020333A1 (en) * 2005-07-20 2007-01-25 Chin-Chih Chiang Controlled release of hypnotic agents
AU2006275702A1 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
AU2006275679B2 (en) * 2005-07-29 2012-04-12 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of Chk2 kinase inhibitors for cancer treatment
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20070128272A1 (en) * 2005-12-07 2007-06-07 Zerbe Horst G Multi-vitamin and mineral supplement
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
EP3124471B1 (de) 2006-03-17 2020-06-03 The Johns Hopkins University N-hydroxylsulfonamid-derivate als neue physiologisch nützliche nitroxylspender
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
EP2120578B1 (de) 2007-01-19 2014-11-19 Xcovery, INC. Kinasehemmerverbindungen
KR20100092928A (ko) 2007-09-26 2010-08-23 존스 홉킨스 유니버시티 신규의 생리적으로 유용한 니트록실 도너로서 ｎ-히드록실술폰아미드 유도체
CA2708400C (en) * 2007-12-28 2016-02-02 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. A slow-release formulation based on an association of glycogen and alginate
LT2278975T (lt) 2008-05-07 2016-11-25 Cardioxyl Pharmaceuticals Inc. Nauji nitrozo junginiai kaip nitroksilo donorai, ir jų panaudojimo būdas
CN102098917B (zh) 2008-06-19 2016-03-16 艾科睿控股公司 作为激酶抑制剂化合物的取代的哒嗪羧酰胺化合物
WO2010042163A2 (en) 2008-10-06 2010-04-15 The Johns Hopkins University Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
WO2011063339A1 (en) * 2009-11-23 2011-05-26 Cardioxyl Pharmaceuticals, Inc. Nitroxyl donors for the treatment of pulmonary hypertension
MX2012006265A (es) 2009-12-03 2012-07-25 Opko Health Inc Formulaciones disacaridas hipersulfatadas.
CN105919987B (zh) 2009-12-07 2020-04-03 约翰斯霍普金斯大学 N-酰氧基磺酰胺和n-羟基-n-酰基磺酰胺衍生物及其用途
CN105130855B (zh) 2009-12-07 2018-05-25 约翰斯霍普金斯大学 二酰基化的羟基胺衍生物及其用途
US20120082720A1 (en) * 2010-10-05 2012-04-05 Sam Poon Ang Compositions For Treating Chronic Viral Infections
US20120082719A1 (en) * 2010-10-05 2012-04-05 Sam Poon Ang Compositions For Treating Chronic Viral Infections
JP6023062B2 (ja) 2010-10-08 2016-11-09 エックスカバリー ホールディング カンパニー エルエルシー 置換ピリダジンカルボキサミド化合物
SG11201401587QA (en) 2011-10-17 2014-07-30 Univ Johns Hopkins Meldrum 's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors
US9676708B2 (en) 2012-11-01 2017-06-13 The Johns Hopkins University Controlled HNO release through intramolecular cyclization-elimination
TWI686193B (zh) 2013-01-18 2020-03-01 美商卡爾迪奧克斯爾製藥公司 具有增進之治療指數的硝醯基予體
WO2014168874A2 (en) 2013-04-07 2014-10-16 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
WO2015109210A1 (en) 2014-01-17 2015-07-23 Cardioxyl Pharmaceuticals, Inc. N-hydroxymethanesulfonamide nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
WO2015183839A1 (en) 2014-05-27 2015-12-03 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
EP3148983A1 (de) 2014-05-27 2017-04-05 The Johns Hopkins University N-hydroxylaminobarbitursäure-derivate als nitroxyldonatoren
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
US10202363B2 (en) 2014-12-23 2019-02-12 Cerecor, Inc. Compounds, compositions and methods
MX2017014700A (es) 2015-05-20 2018-08-15 Broad Inst Inc Neoantigenos compartidos.
CN107750160B (zh) 2015-06-09 2021-06-22 百缮药业(苏州)有限公司 氟代环戊烯基胞嘧啶的用途及制备方法
KR101592144B1 (ko) 2015-06-19 2016-02-04 고려대학교 산학협력단 요오드 캡슐, 이의 제조방법 및 이를 포함하는 소금
WO2017027778A1 (en) 2015-08-13 2017-02-16 Temple University-Of The Commonwealth System Of Higher Education Calcium alginate dosage formulations, and methods of making and using thereof
JP2018526392A (ja) 2015-09-04 2018-09-13 レクサン ファーマシューティカルズ インコーポレイテッド キノキサリニル−ピペラジンアミドの使用方法
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
RS62695B1 (sr) 2016-10-03 2022-01-31 Highlightll Pharmaceutical Hainan Co Ltd Novi jak1 selektivni inhibitori i njihove upotrebe
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CA3097620A1 (en) 2018-05-04 2019-11-07 Tollys Tlr3 ligands that activate both epithelial and myeloid cells
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
EP3955923A1 (de) 2019-04-18 2022-02-23 The Regents Of The University Of Michigan Kombination mit checkpoint-inhibitoren zur behandlung von krebs
AU2021280261A1 (en) 2020-05-26 2023-01-19 Dionis Therapeutics, Inc. Nucleic acid artificial mini-proteome libraries
EP4161508A1 (de) 2020-06-05 2023-04-12 Henry Ford Health System Dakalasvir zur verwendung bei der behandlung von lungen- und prostatakrebs
EP4267554A1 (de) 2020-12-22 2023-11-01 Mekanistic Therapeutics LLC Substituierte aminobenzylheteroarylverbindungen als egfr- und/oder pi3k-hemmer
WO2022189861A1 (en) 2021-03-08 2022-09-15 Tollys Carbohydrate conjugates of tlr3 ligands and uses thereof
EP4385510A1 (de) 2021-08-10 2024-06-19 Betta Pharmaceuticals Co., Ltd Verwendung von ensartinib oder einem salz davon bei der behandlung von krankheiten mit exon-skipping-mutation von met 14
WO2023076733A1 (en) 2021-11-01 2023-05-04 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR985218A (fr) * 1948-04-27 1951-07-16 Medical Alginates Ltd Perfectionnements aux procédé d'application des produits alginatés
US3640741A (en) * 1970-02-24 1972-02-08 Hollister Inc Composition containing gel
DE2062715C3 (de) * 1970-12-19 1974-03-21 Efeka Friedrich & Kaufmann Arzneimittelfabrik, 3000 Hannover Verfahren zur Herstellung von oral applizierbaren Arzneimittelzubereitungen mit protrahierter Wirkstoffabgabe und Arzneimittelzubereitung
DE3583799D1 (de) * 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
JP2971660B2 (ja) * 1991-03-29 1999-11-08 株式会社東芝 超電導磁石装置
JP3000771B2 (ja) * 1991-12-20 2000-01-17 株式会社日立製作所 磁気浮上式走行体とその走行安定方法

Also Published As

Publication number Publication date
EP0188040A1 (de) 1986-07-23
ES550807A0 (es) 1987-05-16
EP0188040B1 (de) 1991-08-14
CA1273873A (en) 1990-09-11
GR860060B (en) 1986-05-12
ES8705757A1 (es) 1987-05-16
DE3583799D1 (de) 1991-09-19
US4842866A (en) 1989-06-27

Similar Documents

Publication Publication Date Title
ATE66143T1 (de) Feste zubereitung mit langsamer freisetzung.
DE3880593D1 (de) Arzneizubereitungen mit retardierter wirkstofffreisetzung.
NL194821B (nl) Farmacologisch actieve catecholderivaten en samenstellingen ervan.
ZA894728B (en) A new pharmaceutical formulation as well as a process for its preparation
IL78111A0 (en) Sulfur-containing 5-substituted benzimidazole derivatives,their preparation and pharmaceutical compositions containing them
MY104065A (en) New pharmaceutical preparation
EP0224146A3 (en) Pharmaceutical preparation for the controlled release of active ingredients
IL78970A (en) 3-(heteroaralkylamino-alkyl)-3-benzazepin-2-one derivatives,their preparation and pharmaceutical compositions containing them
DK143588D0 (da) Substituerede 9-amino-tetrahydroacridiner, deres fremstilling og anvendelse som laegemidler
IL89205A (en) Chloroaniline derivatives, their preparation and pharmaceutical compositions containing them
NO873534L (no) Stabilt farmasoeytisk gelpreparat.
DE68909772D1 (de) Diclofenac-Natrium-Arzneizubereitung mit verlängerter Wirkstoffabgabe.
NO862095L (no) Farmasoeytiske preparater inneholdende vevsplasmnogenaktivitator og fremgangsmaate for deres fremstilling.
DK256488D0 (da) Immunmodulerende farmaceutisk praeparat
NL194749B (nl) Stabiel calciumhoudend farmaceutisch preparaat.
EP0380021A3 (de) Stabilisierungssystem für feste Dosisformen
ES491307A0 (es) Un procedimiento para la preparacion de una composicion de liberacion controlada de un compuesto biologicamente activo para su administracion a un animal
IL80229A0 (en) Flavone derivatives,their preparation and pharmaceutical compositions containing them
DK366888A (da) Castanosperminestre og -glykosider, deres fremstilling og anvendelse som laegemidler
ZA872739B (en) Benzimidazolesulfonamides and imidazopyridine-sulfonamides,their preparation and their application as drugs
DK284688A (da) Beta-lactam-forbindelser, deres fremstilling og anvendelse som laegemidler
IL78432A (en) Dichloroaniline derivatives,their preparation and pharmaceutical compositions containing them
IL85651A0 (en) Optically active oxo-isoindolinyl derivatives,their preparation and pharmaceutical compositions containing them
DK501888D0 (da) 6-mercaptopurin-derivater, deres fremstilling og anvendelse som laegemidler
DK469087A (da) Farmaceutisk praeparat indeholdende et calciumoptagelsesblokerende middel og en ace-inhibitor.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time